Cargando…

Dapagliflozin, advanced chronic kidney disease, and mortality: new insights from the DAPA-CKD trial

Detalles Bibliográficos
Autores principales:	Marx, Nikolaus, Floege, Jürgen
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2021
Materias:	Clnical Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8014504/ https://www.ncbi.nlm.nih.gov/pubmed/33792668 http://dx.doi.org/10.1093/eurheartj/ehab092

Ejemplares similares

Effects of dapagliflozin on mortality in patients with chronic kidney disease: a pre-specified analysis from the DAPA-CKD randomized controlled trial
por: Heerspink, Hiddo J L, et al.
Publicado: (2021)

The dapagliflozin and prevention of adverse outcomes in chronic kidney disease (DAPA-CKD) trial: baseline characteristics
por: Wheeler, David C, et al.
Publicado: (2020)

Effects of Dapagliflozin in Chronic Kidney Disease, With and Without Other Cardiovascular Medications: DAPA‐CKD Trial
por: Chertow, Glenn M., et al.
Publicado: (2023)

Rationale and protocol of the Dapagliflozin And Prevention of Adverse outcomes in Chronic Kidney Disease (DAPA-CKD) randomized controlled trial
por: Heerspink, Hiddo J L, et al.
Publicado: (2020)

Safety and efficacy of dapagliflozin in patients with focal segmental glomerulosclerosis: a prespecified analysis of the dapagliflozin and prevention of adverse outcomes in chronic kidney disease (DAPA-CKD) trial
por: Wheeler, David C, et al.
Publicado: (2021)

Does night-time aircraft noise trigger mortality? A case-crossover study on 24 886 cardiovascular deaths
por: Saucy, Apolline, et al.
Publicado: (2020)

Empagliflozin and health-related quality of life outcomes in patients with heart failure with reduced ejection fraction: the EMPEROR-Reduced trial
por: Butler, Javed, et al.
Publicado: (2021)

Efficacy and Safety of Dapagliflozin by Baseline Glycemic Status: A Prespecified Analysis From the DAPA-CKD Trial
por: Persson, Frederik, et al.
Publicado: (2021)

Effect of dapagliflozin on kidney and cardiovascular outcomes by baseline KDIGO risk categories: a post hoc analysis of the DAPA-CKD trial
por: Waijer, Simke W., et al.
Publicado: (2022)

Efficacy of Dapagliflozin by Baseline Diabetes Medications: A Prespecified Analysis From the DAPA-CKD Study
por: Beernink, Jelle M., et al.
Publicado: (2023)

Midlife blood pressure is associated with the severity of white matter hyperintensities: analysis of the UK Biobank cohort study
por: Wartolowska, Karolina Agnieszka, et al.
Publicado: (2020)

Heart failure and systolic function: time to leave diagnostics based on ejection fraction?
por: Smiseth, Otto A, et al.
Publicado: (2021)

The dark side of nocturnal light pollution. Outdoor light at night increases risk of coronary heart disease
por: Münzel, Thomas, et al.
Publicado: (2020)

Incidence and outcome of atrial fibrillation: diversity throughout Europe
por: Rienstra, Michiel, et al.
Publicado: (2021)

Discriminatory cardiac arrest care? Patients with low socioeconomic status receive delayed cardiopulmonary resuscitation and are less likely to survive an in-hospital cardiac arrest
por: Agerström, Jens, et al.
Publicado: (2020)

Noise and cardiovascular risk: nighttime aircraft noise acutely triggers cardiovascular death
por: Münzel, Thomas, et al.
Publicado: (2020)

Alcohol consumption, cardiac biomarkers, and risk of atrial fibrillation and adverse outcomes
por: Csengeri, Dora, et al.
Publicado: (2021)

Metabolic profiling of angiopoietin-like protein 3 and 4 inhibition: a drug-target Mendelian randomization analysis
por: Wang, Qin, et al.
Publicado: (2020)

Cardiac arrest in COVID-19: characteristics and outcomes of in- and out-of-hospital cardiac arrest. A report from the Swedish Registry for Cardiopulmonary Resuscitation
por: Sultanian, Pedram, et al.
Publicado: (2021)

Unfolding and disentangling coronary vascular disease through genome-wide association studies
por: Erdmann, Jeanette, et al.
Publicado: (2021)

Illuminating the path from genetics to clinical outcome in Brugada syndrome
por: Postema, Pieter G, et al.
Publicado: (2021)

Brugada syndrome genetics is associated with phenotype severity
por: Ciconte, Giuseppe, et al.
Publicado: (2020)

DAPA-CKD: The Beginning of a New Era in Renal Protection
por: Cherney, David Z.I., et al.
Publicado: (2021)

The Dapagliflozin and Prevention of Adverse outcomes in Heart Failure trial (DAPA-HF) in context
por: McMurray, John J V, et al.
Publicado: (2020)

Dapagliflozin and atrial fibrillation in heart failure with reduced ejection fraction: insights from DAPA‐HF
por: Butt, Jawad H., et al.
Publicado: (2021)

Effects of dapagliflozin in DAPA-HF according to background heart failure therapy
por: Docherty, Kieran F, et al.
Publicado: (2020)

Effect of dapagliflozin according to baseline systolic blood pressure in the Dapagliflozin and Prevention of Adverse Outcomes in Heart Failure trial (DAPA-HF)
por: Serenelli, Matteo, et al.
Publicado: (2020)

Cardiovascular Disease in Chronic Kidney Disease: Pathophysiological Insights and Therapeutic Options
por: Jankowski, Joachim, et al.
Publicado: (2021)

Extrapolated longer-term effects of the DAPA-CKD trial: a modelling analysis
por: McEwan, Phil, et al.
Publicado: (2022)

Iron Deficiency in Heart Failure and Effect of Dapagliflozin: Findings From DAPA-HF
por: Docherty, Kieran F., et al.
Publicado: (2022)

Dapagliflozin and Diuretic Use in Patients With Heart Failure and Reduced Ejection Fraction in DAPA-HF
por: Jackson, Alice M., et al.
Publicado: (2020)

Effect of dapagliflozin on ventricular arrhythmias, resuscitated cardiac arrest, or sudden death in DAPA-HF
por: Curtain, James P, et al.
Publicado: (2021)

Dapagliflozin reduces uric acid concentration, an independent predictor of adverse outcomes in DAPA‐HF
por: McDowell, Kirsty, et al.
Publicado: (2022)

Effects of Dapagliflozin in Asian Patients With Heart Failure and Reduced Ejection Fraction in DAPA-HF
por: Docherty, Kieran F., et al.
Publicado: (2022)

Effects of dapagliflozin in heart failure with reduced ejection fraction and chronic obstructive pulmonary disease: an analysis of DAPA‐HF
por: Dewan, Pooja, et al.
Publicado: (2021)

A randomized controlled trial of dapagliflozin on left ventricular hypertrophy in people with type two diabetes: the DAPA-LVH trial
por: Brown, Alexander J M, et al.
Publicado: (2020)

DAPA-HF trial: dapagliflozin evolves from a glucose-lowering agent to a therapy for heart failure
por: Kaplinsky, Edgardo
Publicado: (2020)

Dapagliflozin and Recurrent Heart Failure Hospitalizations in Heart Failure With Reduced Ejection Fraction: An Analysis of DAPA-HF
por: Jhund, Pardeep S., et al.
Publicado: (2021)

Effectiveness and safety of dapagliflozin in real-life patients: data from the DAPA-RWE Spanish multicentre study
por: Morales, Cristóbal, et al.
Publicado: (2022)

The Reporting Frequency of Ketoacidosis Events with Dapagliflozin from the European Spontaneous Reporting System: The DAPA-KETO Study
por: di Mauro, Gabriella, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_k0cserm9fbl6kmgjs483k5b7gd